Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA

Stock Information for Tiziana Life Sciences Ltd

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tiziana Life Sciences Ltd

Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
Tiziana Life Sciences Announces Registered Direct Offering of up to approximately $17.6 Million
Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco
Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA
Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman
Tiziana Life Sciences to Ring the Closing Bell at Nasdaq
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Clinical Trial

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.